Jack Sangster

Jack Sangster is currently a Bioconjugation Scientist at BiVictriX Therapeutics plc, a position held since July 2023. Prior to this role, Jack served as a Research Chemist at Apex Molecular Ltd from November 2022 to July 2023. Jack also gained valuable experience as a Postgraduate Researcher at the Manchester Institute of Biotechnology from September 2018 to November 2022. Jack holds a degree in Chemistry, with a focus on Organic Chemistry, from Heriot-Watt University, completed in 2018.